Prestige Consumer Healthcare Valuation Multiples

Prestige Consumer Healthcare Overview

About Prestige Consumer Healthcare

Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige’s key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer’s Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.

Founded

1996

HQ

Employees

600

Website

prestigebrands.com

Sectors

Health & BeautyBioTech

Financials (LTM)

Revenue: $1B

EBITDA: $363M

EV

$4B

Valuation Multiples

Multiples.vc

Start free trial

Prestige Consumer Healthcare Financials

Prestige Consumer Healthcare reported last 12-month revenue of $1B and EBITDA of $363M.

In the same LTM period, Prestige Consumer Healthcare generated $620M in gross profit, $363M in EBITDA, and $221M in net income.

Prestige Consumer Healthcare P&L

In the most recent fiscal year, Prestige Consumer Healthcare reported revenue of $1B and EBITDA of $374M.

Prestige Consumer Healthcare expects next 12-month revenue of XXX and NTM EBITDA of XXX

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare has current market cap of $3B, and enterprise value of $4B.

Prestige Consumer Healthcare's stock price is $68.53.

Prestige Consumer Healthcare Valuation Multiples

Prestige Consumer Healthcare trades at 3.9x EV/Revenue multiple, and 11.7x EV/EBITDA.

Prestige Consumer Healthcare Financial Valuation Multiples

As of March 26, 2026, Prestige Consumer Healthcare has market cap of $3B and EV of $4B.

Equity research analysts estimate Prestige Consumer Healthcare's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Prestige Consumer Healthcare has a P/E ratio of 14.7x.

Prestige Consumer Healthcare Margins & Growth Rates

Prestige Consumer Healthcare's revenue in the last 12 month grew by 5%.

Prestige Consumer Healthcare's revenue per employee in the last FY averaged $1.8M.

Prestige Consumer Healthcare's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Prestige Consumer Healthcare's rule of X is 44% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Prestige Consumer Healthcare Public Comps

See public comps and valuation multiples for other Health & Beauty comps.

Prestige Consumer Healthcare M&A Activity

Prestige Consumer Healthcare acquired XXX companies to date.

Last acquisition by Prestige Consumer Healthcare was on XXXXXXXX, XXXXX. Prestige Consumer Healthcare acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Prestige Consumer Healthcare Investment Activity

Prestige Consumer Healthcare invested in XXX companies to date.

Prestige Consumer Healthcare made its latest investment on XXXXXXXX, XXXXX. Prestige Consumer Healthcare invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).